close

Mergers and Acquisitions

1 27 28 29 30 31
Number of results: 604
Date Acquired company Acquiring company Amount Related
2011-09-27 Newron (Italy) Biotie Therapies (Finland) €45 million

CNS diseases

2011-09-26 Teva-Kowa Pharma Co (Japan) Teva Pharmaceuticals (Israel) $150 million (€ 110.8 million)

Generic

2011-09-06 Biogen Dompé joint ventures in Italy and Switzerland Biogen Idec (USA) undisclosed

Neurodegenerative diseases
Cancer

2011-08-29 Cellestis (Australia) Qiagen (The Netherlands) $374 million (€ 260 million)
2011-08-26 Bluefish Pharmaceuticals (Sweden) BMM Pharma (Sweden) € 4.16 million

Generic

2011-08-22 Microbiology Business of Biotest AG (Germany) Merck KgaA (Germany) undisclosed

microbiology

2011-07-19 mtm laboratories (Germany) Roche (Switzerland) Under the terms of the agreement, Roche will pay mtm shareholders an upfront payment of approximately €130 million (180 million USD) as well as up to approximately € 60 million (85 million USD) upon reaching performance-related milestones.

In vitro diagnostic

2011-07-19 Argene (France) BioMérieux (France) € 37.5 million with contingent payments of up to € 5 million

Molecular diagnostics

 
2011-07-14 Taiyo Pharmaceutical (Japan) Teva Pharmaceuticals (Israel) $934 million in cash

Generic

2011-07-04 Bioréalités (France) Servier (France) undisclosed

Cancer Oncology

2011-06-30 Cobra Biologics Holding AB (Sweden) Recipharm AB’s shares in Recipharm Cobra Biologics (Sweden)

Manufacturing
Production

2011-06-15 Ipsogen (France) Qiagen (The Netherlands) €70 million

Biomarkers
Personalized healthcare diagnostics

2011-06-14 Shenzhen GSK-Neptunus Biologicals Co. Ltd. (GSKNB) (China) GSK (UK) £24 million (€ 27 million - US$39 million)

Vaccines

2011-06-01 Compound Focus, Inc (compound management business of BioFocus, a Galapagos Company - USA-Belgium) Evotec (Germany) For the acquisition of all shares in Compound Focus Inc. Evotec will pay Galapagos an immediate cash upfront of €10.25M and an additional €2.25M in potential earn out payments upon performance of the business in 2012/2013 depending on revenues and certain corporate milestones.

Pharmaceutical development

2011-05-24 MitoSciences (USA) Abcam (UK) $6.0 million (£3.7 million - €4.25 million)

Mitochondrial research tools
Protein research and detection

2011-05-24 Prometheus Laboratories (USA) Nestlé Health Sciences (Switzerland) undisclosed

Diagnostic
Oncology
Gastroenterology

2011-05-19 Phadia (Sweden) Thermo Fisher Scientific (USA) €2.47 billion

Allergy and Autoimmunity Diagnostics

2011-05-19 Nycomed (Switzerland) Takeda Pharmaceutical (Japan) € 9.6 billion

Gastroenterology
Respiratory diseases
Inflammatory diseases
Pain
Osteoporosis
Tissue management
OTC products

2011-05-17 Advanced BioHealing (USA) Shire (UK - USA) $750 million in cash

Regenerative medicine

2011-05-09 Elan Drug Technologies (formulation and manufacturing business unit of Elan – Ireland) Alkermes (Ireland - USA) $960 Million (€668.7 million)

CNS
Pharmaceutical development